• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Ann S. LaCasce, MD


  • Brown JR, Messmer BT, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, Lacasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS.A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia / small lymphocytic lymphoma.Haematologica. 2013 May 3.
  • Henrich TJ, Hu Z, Li JZ, Sciaranghella G, Busch MP, Keating SM, Gallien S, Lin NH, Giguel FF, Lavoie L, Ho VT, Armand P, Soiffer RJ, Sagar M, Lacasce AS, Kuritzkes DR.Long-Term Reduction in Peripheral Blood HIV Type 1 Reservoirs Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation.J Infect Dis. 2013 Apr 2.
  • Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M.Non-Hodgkin's lymphomas, version 1.2013.J Natl Compr Canc Netw. 2013 Mar 1;11(3):257-72; quiz 273.
  • Abou-Nassar KE, Vanderplas A, Friedberg JW, Abel GA, Niland J, Rodriguez MA, Czuczman MS, Millenson M, Crosby A, Gordon LI, Zelenetz AD, Kaminski M, Lacasce AS.Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database.Leuk Lymphoma. 2013 Feb 25.
  • Armand P, Welch S, Kim HT, LaCasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Coughlin E, Freedman AS, Chen YB.Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.British Journal of Haematology. 2013 Mar;160(5):608-17.
  • Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Naganuma M, Dwyer MA.Non-Hodgkin's Lymphomas, version 3.2012.J Natl Compr Canc Netw. 2012 Dec 1;10(12):1487-98.
  • Barnes J, Jacobsen E, Feng Y, Freedman A, Hochberg E, Lacasce A, Armand P, Joyce R, Sohani A, Rodig S, Neuberg D, Fisher D, Abramson J.Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma.Haematologica. 2012 Nov 9.
  • Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK.Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e647-54.
  • Amrein PC, Attar EC, Takvorian RW, Hochberg EP, Ballen KK, Leahy KM, Fisher DE, Lacasce AS, Jacobsen ED, Armand P, Hasserjian RP, Werner L, Neuberg DS, Brown JR.Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.Clin Cancer Res. 2011 Mar 14.
  • Straus DJ, Johnson JL, Lacasce AS, Bartlett NL, Kostakoglu L, Hsi ED, Schöder H, Hall NC, Jung SH, Canellos GP, Schwartz LH, Takvorian RW, Juweid ME, Cheson BD.Doxorubicin, vinblastine, gemcitabine (CALGB 50203) for stage I/II non-bulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.Blood. 2011 Feb 25.
  • Shinagare AB, Ramaiya NH, O'Regan K, Jagannathan JP, Hornick JL, Lacasce AS.Helicobacter pylori-Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.J Clin Oncol. 2011 Jan 18.
  • Jacobson CA, LaCasce AS.Lymphoma: risk and response after solid organ transplant.Oncology (Huntingt). 2010 Sep;24(10):936-44. Review.
  • Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, Cui Y, Busman T, Elmore SW, Rosenberg SH, Krivoshik AP, Enschede SH, Humerickhouse RA.Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.Lancet Oncol. 2010 Dec;11(12):1149-59.
  • Furman RR, Martin P, Ruan J, Cheung YK, Vose JM, Lacasce AS, Elstrom R, Coleman M, Leonard JP.Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.Cancer. 2010 Dec 1;116(23):5432-9.
  • Barnes JA, Lacasce AS, Zukotynski K, Israel D, Feng Y, Neuberg D, Toomey CE, Hochberg EP, Canellos GP, Abramson JS.End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma.Ann Oncol. 2010 Oct 15.
  • Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, Marcus KJ, Stevenson MA, Chen MH, Ng AK.Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation.Blood. 2010 Sep 21.
  • Lee AI, Zuckerman DS, Van den Abbeele AD, Aquino SL, Crowley D, Toomey C, Lacasce AS, Feng Y, Neuberg DS, Hochberg EP.Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis.Cancer. 2010 Aug 15;116(16):3835-42.
  • Punnoose LR, Roh JD, Hu S, Udell JA, Wagle N, Kirshenbaum JM, Lacasce AS.Cardiac Presentation of Anaplastic Large-Cell Lymphoma.J Clin Oncol. 2010 Jul 1;28(19):e314-6.
  • Chen YB, Hochberg EP, Feng Y, Neuberg D, Rawal B, Motyckova G, Fisher DC, McAfee SL, Spitzer TR, Lacasce AS.Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone.Leuk Lymphoma. 2010 May;51(5):789-96.
  • Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA.Inhibition of Syk with fostamatinib disodium has significant clinical activity in non Hodgkin's lymphoma and chronic lymphocytic leukemia.Blood. 2010 Apr 1;115(13):2578-85.
  • Canellos GP, Abramson JS, Fisher DC, Lacasce AS.Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma With Chemotherapy Without Consolidation by Radiation Therapy.J Clin Oncol. 2010 Mar 20;28(9):1611-5.
  • Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Mughal TI, Nademanee A, Porcu P, Press O, Prosnitz L, Reddy N, Smith MR, Sokol L, Swinnen L, Vose JM, Wierda WG, Yahalom J, Yunus F.NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas.J Natl Compr Canc Netw. 2010 Mar;8(3):288-334.
  • Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP.Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.J Clin Oncol. 2009 Dec 20;27(36):6101-8.
  • Sher DJ, Mauch PM, Van Den Abbeele A, Lacasce AS, Czerminski J, Ng AK.Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy.Ann Oncol. 2009 Nov;20(11):1848-53.
  • Kelly JL, Toothaker SR, Ciminello L, Hoelzer D, Holte H, LaCasce AS, Mead G, Thomas D, Van Imhoff GW, Kahl BS, Cheson BD, Magrath IT, Fisher RI, Friedberg JW.Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.Clin Lymphoma Myeloma. 2009 Aug;9(4):307-10.
  • Lee AI, LaCasce AS.Nodular lymphocyte predominant Hodgkin lymphoma.Oncologist. 2009 Jul;14(7):739-51. Review.
  • Faris JE,LaCasce AS.Primary mediastinal large B-cell lymphoma.Clin Adv Hematol Oncol. 2009 Feb;7(2):125-33.
  • Armand P,Gannamaneni S,Kim HT,Cutler CS,Ho VT,Koreth J,Alyea EP,LaCasce AS,Jacobsen ED,Fisher DC,Brown JR,Canellos GP,Freedman AS,Soiffer RJ,Antin JH.Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.J Clin Oncol. 2008 Dec 10;26(35):5767-74.
  • Kho ME,Lepisto EM,Niland JC,Friedberg JW,Lacasce AS,Weeks JC.Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multicenter outcomes database.Cancer. 2008 Dec 1;113(11):3209-12.
  • Oton AB,Wang H,Leleu X,Melhem MF,George D,Lacasce A,Foon K,Ghobrial IM.Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant.Leuk Lymphoma. 2008 Sep;49(9):1738-44.
  • LaCasce AS,Kho ME,Friedberg JW,Niland JC,Abel GA,Rodriguez MA,Czuczman MS,Millenson MM,Zelenetz AD,Weeks JC.Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network.J Clin Oncol. 2008 Nov 1;26(31):5107-12.
  • Brown JR,Neuberg D,Phillips K,Reynolds H,Silverstein J,Clark JC,Ash M,Thompson C,Fisher DC,Jacobsen E,LaCasce AS,Freedman AS.Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders.British Journal of Haematology. 2008 Nov;143(3):361-8.
  • Chen YB,LaCasce AS.Enzastaurin.Expert Opin Investig Drugs. 2008 Jun;17(6):939-44. Review.
  • Zelenetz AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F.Non-Hodgkin's Lymphomas.J Natl Compr Canc Netw. 2008 Apr;6(4):356-421.
  • Lacasce AS, Freedman AS.Antibody and Immunomodulatory Agents in the Treatment of Indolent Non-Hodgkin's Lymphoma.Semin Hematol. 2008 Apr;45(2):85-9. Review.
  • Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP.Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.Biol Blood Marrow Transplant. 2008 Apr;14(4):418-25.
  • Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, Rowland K, Cruz JC, Goldberg SL, Musib L, Darstein C, Enas N, Kutok JL, Aster JC, Neuberg D, Savage KJ, LaCasce A, Thornton D, Slapak CA, Shipp MA.Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.J Clin Oncol. 2007 May 1;25(13):1741-6.
  • Rodig SJ, Savage KJ, LaCasce AS, Weng AP, Harris NL, Shipp MA, Hsi ED, Gascoyne RD, Kutok JL.Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma.Am J Surg Pathol. 2007 Jan;31(1):106-12.
  • Jacobsen E, LaCasce A.Update on the therapy of highly aggressive non-Hodgkin's lymphoma.Expert Opin Biol Ther. 2006 Jul;6(7):699-708. Review.
  • Zelenetz AD, Advani RH, Buadi F, Cabanillas F, Caligiuri MA, Czuczman MS, Damon LE, Fayad L, Flinn IW, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Kaminski MS, Lacasce AS, Nademanee A, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J.Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.J Natl Compr Canc Netw. 2006 Mar;4(3):258-310.
  • Feuerhake F, Kutok JL, Monti S, Chen W, Lacasce AS, Cattoretti G, Kurtin P, Pinkus GS, de Leval L, Harris NL, Savage KJ, Neuberg D, Habermann TM, Dalla-Favera R, Golub TR, Aster JC, Shipp MA.NF{kappa}B activity, function and target gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes.Blood. 2005 Aug 15;106(4):1392-9.
  • Lacasce A, Howard O, Lib S, Fisher D, Weng A, Neuberg D, Shipp M.Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity.Leuk Lymphoma. 2004 Apr;45(4):761-7.
  • Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A, Mauch PM, Gribben JG, Ritz J, Nadler LM, Soiffer RJ, Freedman AS.Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma.J Clin Oncol. 1999 Oct;17(10):3128-35.
  • Johnson RC, Mayadas TN, Frenette PS, Mebius RE, Subramaniam M, Lacasce A, Hynes RO, Wagner DD.Blood cell dynamics in P-selectin-deficient mice.Blood. 1995 Aug 1;86(3):1106-14.